Conditions: Allergic Rhinoconjunctivitis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 199
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the tolerability of AVANZ.

Detailed description:
To assess the tolerability of the up-dosing phase of AVANZ Phleum pratense. The frequency of patients with adverse reactions will be the study primary endpoint.

Arms:
arm 1: AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection

Interventions: intervention 1: AVANZ Phleum pratense
Intervention descriptions: intervention 1: AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection

Protocol document: